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We have deleted the word significant from the last sentence in the abstract and we have 
added this phrase in patients with trigeminal neuralgia and its variants to tables 5 and 6.  
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Impact of TN  
Abstract  
There is a lack of prospective systematic studies on the clinical characteristics of pain in 
trigeminal QHXUDOJLD71DVZHOODVLWVµSV\FKRVRFLDOEXUGHQ¶.  
Patients with idiopathic TN were categorised into three sub-types (n = 225). Group 1 (n= 
155, 68.9%) had TN without concomitant pain, Group 2 (n=32, 14.2%) had TN with 
intermittent concomitant pain and Group 3 (n=39, 16.9%) had TN with autonomic 
symptoms.  We tested two hypotheses: (i) that different pain profiles would be associated 
with the different groups; (2) that the severe pain associated with TN would impact 
negatively on activities of daily living and thereby result in disability as defined by the 
World Health Organisation. A different pain profile was found across the groups. We 
obtained unequivocal evidence that TN causes disability with up to 45% of patients being 
absent from usual daily activities 15 days or more in the past 6 months.  On the Hospital 
Anxiety and Depression Scale, 35.7% patients had mild to severe depression and over 
50% were anxious.  The Pain Catastrophizing Scale showed that 78% of patients had 
considerable negative thoughts with scores > 20 and a mean score of 36.4. Prior to 
referral only 54% had been prescribed carbamazepine whilst opioids had been prescribed 
in 14.6% of the patients. Prior to referral over 80% had already been to one specialist 
centre which had not provided appropriate management. Patients with TN report varied 
characteristics but all result in some degree of psychosocial disability especially before 
adequate therapy is attained. 
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Abstract  
There is a lack of prospective systematic studies on the clinical characteristics of pain in 
trigeminal QHXUDOJLD71DVZHOODVLWVµSV\FKRVRFLDOEXUGHQ¶.  
Patients with idiopathic TN were categorised into three sub-types (n = 225). Group 1 (n= 
155, 68.9%) had TN without concomitant pain, Group 2 (n=32, 14.2%) had TN with 
intermittent concomitant pain and Group 3 (n=39, 16.9%) had TN with autonomic 
symptoms.  We tested two hypotheses: (i) that different pain profiles would be associated 
with the different groups; (2) that the severe pain associated with TN would impact 
negatively on activities of daily living and thereby result in disability as defined by the 
World Health Organisation. A different pain profile was found across the groups. We 
obtained unequivocal evidence that TN causes disability with up to 45% of patients being 
absent from usual daily activities 15 days or more in the past 6 months.  On the Hospital 
Anxiety and Depression Scale, 35.7% patients had mild to severe depression and over 
50% were anxious.  The Pain Catastrophizing Scale showed that 78% of patients had 
considerable negative thoughts with scores > 20 and a mean score of 36.4. Prior to 
referral only 54% had been prescribed carbamazepine whilst opioids had been prescribed 
in 14.6% of the patients. Prior to referral over 80% had already been to one specialist 
centre which had not provided appropriate management. Patients with TN report varied 
characteristics but all result in some degree of psychosocial disability especially before 
adequate therapy is attained. 
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1. Introduction  
Trigeminal neuralgia (TN) is defined by the International Association for the Study of Pain 
(IASP) as ³a sudden, unilateral, severe brief stabbing recurrent pain in the distribution of one 
or more branches of the fifth cranial nerve´ 19.  The disorder is often misdiagnosed, being 
commonly confused with toothache or temporomandibular disorders, with reports of patients 
undergoing unnecessary, aggressive and irreversible dental treatments before obtaining a 
correct diagnosis 6,29;30. The estimated misdiagnosis by general practitioners could be as high 
DVZKLFK OHG WRD µQHXURORJLVWYDOLGDWHG¶GLDJQRVLV LQFLGHQFH UDWHRISHU
person years in the Netherlands 11.    
 
Although a relatively rare condition, the impact on the lives of patients is profound 1, 31.  
Allsop et al 1 provided a qualitative study suggesting TN places a large burden on patients 
and TN is known to be associated with severe pain 16. Nevertheless, there are few studies that 
have determined the impact of the pain on the lives of the affected individuals. This is highly 
problematic as it prevents proper evaluation of the health economics associated with existing 
treatment for these patients. In turn, this prevents evaluation of alternative treatment 
regimens. We hypothesised that the pain associated with TN would cause a high degree of 
disability (as defined by the World Health Organisation, WHO) within the population. The 
IUDPHZRUNGHVFULEHGLQWKH:+2¶VLQWHUQDWLRQDOFODVVLILFDWLRQRIIXQFWLRQLQJGLVDELOLW\DQG
health (ICF) outlines how impairment (e.g. pain) relates to disability. The ICF identifies three 
levels: the body function and structure level; the activity level and the participation level 
(WHO 2001). The ICF framework suggests that a functional deficit does not automatically 
result in an activity limitation or participation restriction. Rather, these different levels are 
proposed to interact with each other in a complex manner (mediated by personal and family 
factors). There are three studies that support the general idea that the pain associated with TN 
will lead to disability. Tolle et al 24 found a significant impact of TN on activities of daily 
living in their study of 82 patients, mean pain interference of 3.6+2.4 . Wu et al 27 reported 
that TN was associated with increased depression 2.2%, anxiety 1.8%  and sleep disturbance 
1.2% in a retrospective study of 3273 TN patients compared to controls 13,092 based on 
KHDOWK LQVXUDQFH FODLPV GDWDEDVHV 0DþLDQVN\Wơ HW DO 17 identified disability, anxiety and 
depression in 30 to 47% of  30 TN patients.  
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The aim of the current study was to collect detailed clinical characteristics from patients 
attending a TN clinic. We wished to determine the burden of TN at the point of referral to the 
specialist centre. Our goal was explore differences between three groups of patients. Group 1 
- 7\SH  RU µFODVVLFDO¶ ZLWKRXW FRQFRPLWDQW SHUVLVWHQW SDLQ LUUHVSHFWLYH RI QHXURYDVFXODU
compression findings; Group 2 - Type 2 with intermittent concomitant pain often associated 
ZLWKµDIWHU-SDLQ¶IROORZLQJDQDWtack 21 ;  Group 3 - TN with autonomic symptoms which are 
either present consistently or intermittently. We wanted to explore whether these different 
classifications produced different pain profiles (thereby supporting the clinical utility of this 
categorisation). 
 
2. Material and Methods   
 
2.1 Study subjects  
We enrolled 237 consecutively  consenting patients with TN (and its variants - short-lasting 
unilateral neuralgiform headache attacks with autonomic system symptoms (SUNA) or short-
lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing 
(SUNCT)) into a cohort study between April 2007 and December 2015. The patients were all 
attending a national Facial Pain Unit within a London teaching hospital. Patients with 
multiple sclerosis or tumour related TN (n = 12) were excluded but those who had undergone 
previous surgery for TN were included if their pain was the same as pre-operatively. The 
resulting cohort (n = 225) undertook a baseline assessment that comprised both physician 
measures and patient-completed questionnaires.  
 
2.2 Ethics approval  
The project had ethical approval and all patients were provided with an information sheet and 
gave written consent according to the Declaration of Helsinki.  The study was approved by 
South East Research Ethics Committee REC Reference Number 07/MRE01/38. 
 
2.3 Patient history of TN  
Basic demographic data including ethnicity and social status were recorded. A note was made 
regarding the specialists seen prior to attendance. The medical history was ascertained from 
the primary care physician (GP) and particular note was made of conditions associated with 
TN and the presence of headaches, migraines and other chronic pain. All current and past 
treatments for TN were recorded including maximum doses and, where possible, efficacy and 
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tolerability. Patients were asked about any history of bruxism (teeth grinding), jaw clenching 
habits and jaw clicking. Examination included a gross cranial nerve examination and sensory 
testing with light touch, cotton wool and pin-prick. The muscles of mastication were 
examined for tender spots to determine if a musculoskeletal temporomandibular disorder was 
present and an oral examination was done.  
 
$KLVWRU\RI WKHSDWLHQW¶V H[SHULHQFHZDV FROOHFWHG GXUDWLRQRQVHW LQFOXGLQJZKHWKHU WKLV
was acute and memorable (i.e. could they remember the circumstances of the first attack); 
length of attacks; whether these were single stabs, a series of stabs in quick succession or 
PRUH FRQWLQXRXV µVDZ WRRWK¶ 5 ZKHWKHU DQ\ µDIWHU SDLQ¶ UHPDLQHG DQG LWV GXUDWLRQ DQG
characteristics; remission periods and their length; provoking factors (including whether 
attacks were only evoked or could be spontaneous). The pain location for the third division 
was noted and whether this remained only in the lower part of the face ie. Pre-auricular area 
down to the mental area or extended to the temporal region. 
 
2.4 Patient questionnaires 
Pain ascertainment  
Patients completed the following questionnaires at their first visit: The Brief Pain 
Inventory 4 ,13 which uses a Lickert (1-10) scale to determine pain intensity and quality 
of life (an extended one was introduced later); The Graded Chronic Pain Scale  (GGPS) 
26
 which uses a Lickert (1-4) scale to determine pain over last six months; The McGill 
pain questionnaire, where users select words that best describe their pain 18; The Pain 
Catastrophizing Scale (PCS) 23 to assess catastrophizing (scores > 20 deemed 
µVLJQLILFDQW¶).  
Depression and anxiety ascertainment  
The Hospital Anxiety and Depression scale (HAD) 32 scores > 8 significant  replaced the 
DAPOS to assess depression which  was used for the first year only; plus two NICE 
questions to screen for depression 22. 
Data collection  
Each patient was assigned a unique study ID number. A standardised data extraction form 
and simple UCLH/ University of Leeds TN patient data base was developed to facilitate the 
data collection. The patient data were transferred from the paper case report form into the TN 
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database (quality of inputting audited). Patients were followed up via routine clinical 
consultations and self-completed questionnaires. All patients were seen by one clinician (JZ), 
with 58 (26%) also seen by a headache neurologist to independently validate the diagnosis. 
All patients had an MRI to exclude a symptomatic cause and identify potential neurovascular 
compression, some of which had been done prior to referral.  Patients were managed 
according to the Facial Pain Unit protocol, similar to the recently published Danish protocol 
9
. Questionnaires were collected at each routine visit.   
 
2.5 Statistical  Analysis   
A case series analysis was performed. Summary statistics were used to describe the sample: 
means and standard deviations were provided for continuous variables and frequency 
distributions for categorical variables. One-way ANOVAs were used for continuous 
outcomes and chi-squared tests were used for categorical outcomes (significance level set at 
5%). Pain severity was categorized as mild, moderate, or severe.  
 
3. Results  
 
A total of 237 patients were referred to the clinic between 2007 and 2015. Twelve of these 
patients (5.1%) had TN secondary to other causes and were excluded from further analysis. 
Nine of these 12 patients (6 women and 3 men) had multiple sclerosis before the onset of 
their TN, three had tumours.. The remainder (n = 225) were divided into three groups: Group 
1 TN (n= 155) had TN without concomitant pain, Group 2 TNC (n=32) had TN with at least 
some concomitant pain and Group 3 TNA (n=38) had TN with autonomic system symptoms. 
Group 3 contained 13 patients that could be classified as SUNA/SUNCT with the rest having 
only intermittent autonomic symptoms.  The 23 patients who had had previous surgery fell 
within Group 1 (n = 15), Group 2 (n = 3) and Group 3 (n = 5, with 3 patients having SUNA).  
Table 1 provides details of type of surgery they had and its effect.  
 
[TABLE 1 AROUND HERE] 
 
3.1 Baseline characteristics 
The baseline demographic and clinical characteristics of the 225 patients are presented in 
Table 2. The mean (SD) age was 60.9 (12.5) years, and the median age [IQR] at first attack 
was 57.0 [46.0, 65.0] years. The median duration of TN was 4.0 [2.0, 7.0] years. There were 
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no statistically significant differences in symptom duration or age between the three groups.  
There was a predominance of females (63.6%) within the population. There was a bias 
towards a higher socioeconomic position within the population, with over 70% of the patients 
having an index of multiple deprivation of 3 or less (1 = least deprived and 5 = most 
deprived). Two thirds of the patients (63.7%) had managerial or professional occupations 
according to the standard occupational classification (Office for National Statistics 2010).   
 
[TABLE 2 AROUND HERE] 
   
A family history of TN was reported by 13 (5.8%) of the patients. Nearly half of the patients 
(45.7%) were referred to the clinic by a primary care medical practitioner (GP), a fifth were 
referred by a dentist with the rest referred by specialists. There was not a statistically higher 
incidence of lower facial pain in those referred by a dentist. Prior to referral, the majority of 
the patients had already consulted a GP (80.0%) or dentist (71.6%). Many had used 
secondary dental (42.2%) or medical (58.7%) services and 32.5% had seen two or more 
dental or medical specialists. One hundred and fifteen patients (87.1%) had seen a 
neurosurgeon or neurologist or both.  
 
3.2 Medical history and oral health 
A quarter of patients had headaches and 44 had migraines or migraines with tension type 
headache (10 of these were in Group 3). Patients in all groups had a similar incidence of 
hypertension (37.3%) and other cardiovascular diseases (12.4%) and those proportions were 
lower than the population prevalence (hypertension 52.0% and cardiovascular disease 22%) 
of similar age (table 3). Fifty four patients (24.0%) reported bruxism but the frequency was 
not different between groups. The quality of oral hygiene was evenly distributed among poor 
(31.5%), moderate (28.9%) and good (31.5%) quality for 108 patients who were examined. 
Two hundred and eleven patients had partial/full dentition and only 24 (14.3%) patients had 
little conservation but all had evidence of some dental treatment. Oral health was not 
associated either with the duration of TN or pain severity.  
 
 [TABLE 3 AROUND HERE]  
 
3.3 Pain characteristics 
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The pain locations for Group 1 (n = 155) and Group 2 (n = 32) were similar in all trigeminal 
divisions.  In contrast, those patients in Group 3 (n = 38) had a significantly lower proportion 
of pain in the first division of the trigeminal nerve and third division (0% and 10.3%) but a 
higher proportion of pain in the second division (Table 4). Right-sided TN (65.6%) was twice 
as prevalent as left-sided TN (32.5%), while 1.9% of the patients had bilateral TN. All 
patients had extra-oral pain but 79.9% also reported intra-oral pain (whereas 68.6% reported 
only extra-oral pain) across all type of TN.  
 
[TABLE 4 AROUND HERE] 
 
Patients reported a variety of different types of attacks. The predominant type of attack was a 
single stab for all groups but a series of stabs was also frequently reported in Group 1 
(36.4%) and Group 2 (31.3%) and patients would also report having a combination of these 
types. Pain severity was similar across the three types of TN. Less than 5% of patients in 
Group 1 and 3 could not recall the circumstances of the first attack while a fifth of Group 2 
(79.3%) could not remember the circumstances (p-value = 0.001).  
 
The pain frequency in TN is high with over 90% reporting daily pain attacks though only a 
small proportion reported attacks on an hourly basis. Very few patients reported attacks 
lasting more than a few minutes but 62% of Group 2 reported a prolonged after-pain.  
 
Remission periods were reported consistently across the groups but were least likely to be in 
Group 3. Overall, the remission duration decreased with time. Nearly all patients had 
spontaneous pain but all had pain provoked by light touch on the face or intra-orally. A large 
proportion of patients across all TN types (30-60%; p-value = 0.05) could be provoked by 
cold wind or bodily movement. Four patients had attacks that could be provoked by noise or 
light and one patient had attacks that could be provoked by alcohol. Group 3 reported the 
most ipsilateral autonomic features (p-value = <0.001) and the most common ones were 
tearing, nasal stuffiness, redness of the cheek or eye, and these were all statistically different 
from the other groups (p-value <0.001) (see table 3). These were not observed but reported 
several times at follow ups.   
 
The McGill pain questionnaire was fully completed by 193 of the 225 patients (85.8%). The 
words were analysed by sensory type (1-10), affective type (11-15), evaluative type (16) and 
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miscellaneous type (17-20). The sensory words most commonly used by patients across all 
*URXSVZHUHµVKRRWLQJ¶IROORZHGE\µVKDUS¶DQGµVWDEELQJ¶0RUH
WKDQRISDWLHQWVFKRRVHDZRUGIURPµIHDUIXO¶µIULJKWIXO¶RUµWHUULI\LQJ¶7KHHYDOXDWLYH
and miscellaneous words most commonly chosen in all TN FDWHJRULHV ZHUH µXQEHDUDEOH¶
DQGµSLHUFLQJ¶ 
 
3.4 Treatment 
Pharmacological management of TN was the most commonly reported treatment modality for 
TN. All patients received at least one medication for their facial pain before referral. A 
quarter of the patients (27.6%) had two medications while nearly half (46.7%) had used three 
or more medications. Prior to referral, the most frequently prescribed drug was 
carbamazepine (including retard type) 122/225 (54.2%) which also caused significant side 
effects. Opioids had been prescribed in 14.6% of the patients. Over 75% were put on 
anticonvulsants after the first consultation as shown in figure 1.   
 
[FIGURE 1 AROUND HERE] 
 
3.5 Impact of pain 
Pain had a significant impact on health status, including functioning and well-being across all 
TN groups as shown in Table 4. On the NICE questions, 106/216 (49.1%) felt depressed and 
101/216 (47.6%) had little pleasure in life. This correlated with the HAD results where 
75/210 (35.7%) patients had mild to severe depression. More than 50% were anxious as 
indexed by the HAD. The Pain Catastrophizing Scale (PCS) showed that a significant 
proportion of patients with TN had considerable negative thoughts about their pain:  146/188 
(77.7%) patients had a PCS score of 20 and over with a mean score of 36.4 (95% CI: 34.9-
37.9). 
 
Completion of the CGPS questionnaire (grading pain in the past 6 months) achieved 175/225 
(77.8%) respondents.  Ninety five of these patients (54.3%) had high and moderately or 
severely limiting disability (Grade III and IV). 89/198 (44.9%) patients were absent from 
usual daily activities (work, school or housework) 15 days or more in the past 6 months 
because of the facial pain. The CGPS was significantly associated with HAD -Anxiety (p < 
0.001) and HAD -'HSUHVVLRQSXVLQJ3HDUVRQ¶V&KL-square test, table 5. 
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[TABLE 5 AROUND HERE] 
 
On the Brief Pain Inventory (BPI)±Facial, reporting pain intensity and impact in the week 
prior to assessment, two thirds (66.3%) of patients reported moderate (score of 4-7) or severe 
(score of 7-10) overall pain within the prior 24 hours and the mean overall Pain Severity 
Index scores for 194 patients was 3.9 (95% CI: 3.6-4.3), indicating a mild to moderate level 
of pain. The pain severity was significantly associated with HAD-Depression (p = 0.022) but 
not HAD -$Q[LHW\S XVLQJ3HDUVRQ¶V&KL-square test table 6.  
 
[TABLE 6 AROUND HERE] 
 
The mean pain interference on the BPI was higher (mean = 4.9) when the facial domains 
were assessed. The pain interference was more salient for 110 patients who also reported pain 
interference on seven face related daily activities (mean 4.9, 95% CI: 4.3-5.5). Pain severity 
significantly affected general activity, mood and enjoyment of life (Figure 2). Sleep was 
affected for those with severe pain, with thirty five patients reporting that pain affected their 
sleep. Pain severely interfered with all daily activities, especially activities involving the face 
(such as eating a meal, brushing or flossing teeth and eating hard food like apples) as seen in 
Figure 3.  
 
[FIGURE 2 AND 3 AROUND HERE] 
 
4. Discussion  
 
The reported research represents the largest and most comprehensive biopsychosocial 
prospective study on TN that has been conducted to date.  
 
4.1. Population characteristics  
The study involved a population of patients with TN who attended a specialist clinic. In this 
regard, the population may not be representative of the general TN population (as less severe 
cases may not end up at such a specialist clinic). Indeed, the average socioeconomic position 
of the population was skewed away from the greatest levels of deprivation. It seems likely 
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that TN (like most other diseases including multiple sclerosis ) would be over represented in 
lower socioeconomic positions. Thus, the population reported within this paper are probably 
overrepresented with those who could utilise social capital to attend the clinic.  Patients 
access many health care professionals prior to referral to a specialist clinic. These clinics can 
provide appropriate treatment but over 37% of those visiting a dentist get dental treatment 
which is often irreversible (such as root canal treatments and extractions) which contribute to 
the burden 16 .  Garvan and Siegfried 6 reported that in their series of 140 patients 67 patients 
had 680 teeth extracted. Patients with only intraoral pain may obtain continuing care from 
dental practitioners and not be referred whereas patients in Group 3 may be more complex 
and less responsive to carbamazepine and so referred in earlier.  Repeated consultations and 
inappropriate use of medications (despite numerous guidelines) add to the economic costs to 
the providers and the patients.  
 
4.2 TN variants  
The participants were considered as falling within one of three groups. Group 1 had TN 
without concomitant pain, Group 2 had TN with concomitant pain and Group 3 had TN with 
autonomic symptoms.   We hypothesised that the different groups would show disparate pain 
profiles. There were clear differences between the groups. Group 3 were more likely to have 
a lower proportion of pain in the lower part of the face and had prominent autonomic 
symptoms. Groups 1 and 2 were more likely to experience a series of stabbing pains, with 
Group 2 more likely to experience a prolonged after-pain and were less likely to recall the 
circumstances of their first attack. We observed in our cohort that 68.4% had TN without 
concomitant pain and 14.2% had TN with at least some concomitant pain and 30% had 
attacks lasting minutes rather than seconds ± this was a distinctive difference to the 
Maarbjerg et al 15 cohort who had 49% with concomitant pain. This might be explained by 
differing clinical referral processes  to a specialist headache neurology clinic compared to  
ours , a specialist facial pain clinic within a dental school15. Haviv et al 8 hypothesised that 
length of individual pain attacks correlates to presence of background pain - a similar finding 
to this cohort. They reported that 87% of those with attack duration of over 2 minutes (n= 20) 
had background pain whereas this was 30% in those with shorter attacks.  Bowsher 3 reported 
that 50% of 50 patients who had prior surgery reported longer attack duration but, in the 
present study, the 10.2% who had undergone surgery were not significantly different from the 
rest of the population (except for having consulted more specialists).  
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In agreement with other studies, our work shows that autonomic features are often present 
and this is reflected in emerging data showing that SUNCT, SUNA and TN may be variants 
of the same disorder 12,25. Patients did report some altered sensation and this was highest in 
Group 2. This may be of importance as a recent study has suggested that classical TN (Group 
1) may have sub-clinical hypoesthesia whereas those with concomitant pain (Group 2) were 
more likely to have more clinically detectable sensory changes but all had sensory changes 
not just on the side of pain but also on the opposite side and in other parts of the body 
suggesting central sensitisation 28.   What still needs to be established is whether patients 
move between the different groups during the course of disorder.   
  
4.3 Clinical characteristics  
This study has provided useful information on the clinical characteristics of TN patients. Our 
results concur with a large UK population study that showed greater prevalence in women 
and a higher occurrence of right-sided symptoms and pain in second and third divisions that 
is consistent with the somatology relationship of sensory fibres in the trigeminal nerve Hall et 
al 7.  The study has highlighted that pain in the third division may only involve the lower 
branches and not the temporal branches does not always extend to the entire third division 
and is often present only in the lower division as proposed by Henderson 10 who suggests a 
mouth ±ear zone and nose-orbit zone.  Other features, including the McGill pain descriptors, 
are similar to other studies reporting on phenotypic features 3,8,16 and highlights the frequent 
XVHRIZRUGVOLNH³IHDUIXO´DQG³WHUULI\LQJ´)HDUFRXOGEHDGULYHUIRUWKe spontaneous pain 
rather than evoked pain as shown in a small fMRI study done with patients with classical TN, 
where patients were told that their pain would be triggered during the examination 20.  
 
4.4 Management  
Pharmacological management is the most commonly used treatment modality for patients 
with TN. The anticonvulsant class (particularly carbamazepine) is considered the gold 
standard treatment 30. It is clear though that a wide range of drugs are being provided to TN 
patients and over 75% have used more than one drug prior to referral with 21% having used 
four or more.  The prescribed drugs include opioids despite the lack of any evidence that 
these drugs are effective in TN. Despite all the guideline recommendations only 54% of the 
patients were or had used carbamazepine which agrees with Hall HWDO¶V7 survey of primary 
care management of TN (where the figure was 58%). An additional 37 patients were 
prescribed this drug after their attendance at the clinic and other non-effective drugs were 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
The impact of Trigeminal Neuralgia 
 
13 
 
stopped.  This suggests that large numbers of TN patients outside specialist clinics are not 
being provided with the optimal drug regime which adds to the burden of their disease. The 
effectiveness of carbamazepine/retard was witnessed by the fact that 91.8% of the patients 
taking this drug reported that it was partially or completely effective. Unfortunately, 42.8% of 
these patients reported significant side effects which is to be expected as all these drugs result 
in side effects - especially cognitive side effects 2.  
 
4.5 Burden of disease  
The results of the present study provide further empirical evidence that patients with TN 
suffer considerable pain and disability ± even when prescribed the optimal drug regimen. We 
hypothesised that the high levels of pain ZRXOGSURGXFHGLVDELOLW\DVGHILQHGE\WKH:+2¶V
International Classification of Disability. The data showed unambiguously that patients with 
TN experience considerable activity limitation and the limitation is particularly pronounced 
with activities that involve the face (e.g. eating a hard piece of food, such as an apple). 
Moreover, there was a relationship between pain and the ability of the patients to participate. 
We found evidence that over 50% of the patients had to take significant time off work which 
has a significant economic impact as the median age for the start of the TN is 57 and over 
50% are still in employment. This has never previously been reported.  The disability 
experienced by patients with TN is consistent with the high levels of anxiety and depression 
recorded within this population. Fear, unpredictability of the pain attacks and lack of 
confidence in dealing with flare ups results in high catastrophizing scores.   
 
The quantitative data in the present study are consistent with the qualitative data reported in 
Allsop et al 1. The overall picture suggests a population who have a high chance of 
experiencing excruciating pain, leading to activity limitation and participation restriction. 
These findings suggest that patients with TN should be offered psychological support ±this is 
not routinely provided at present. A multidisciplinary approach for pain management 
(including, for example, Cognitive Behavioural Therapy) can be effective for pain control, 
developing coping skills and restoration of functional status. It is important that patients with 
TN are provided with an individualised pain management programme that is not limited to 
pharmacological or surgical interventions alone.  
 
5. Conclusions   
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We conclude that patients with TN are experiencing a poor quality of life even when being 
treated with the optimal drug regimen. This suggests an urgent need to evaluate alternative 
treatment pathways (such as newer medications, psychological support, earlier surgical 
interventions and access to newer surgical innovations such stereotactic radiosurgery, 
neuromodulation). For example, Lee et al 14 have suggested that surgical management can 
significantly improve quality of life in patients with TN when assessed using the Brief Pain 
Inventory ±Facial. The data presented in the current manuscript provides a starting point for 
evaluations of the true health burden and cost of TN. 
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Legends for Figures  
 
Figure 1. Medication type prescribed before and after referral. Legend: sky blue-Antibiotics, 
red-Anticonvulsant, grey-Antidepressants, orange-Analgesics, blue-OTC Analgesics, black-
Opioids, dark blue-Others 
 
Figure 2. Association between Pain Severity and Interference on Health Status Domains and 
general daily activities. Legend: sky blue-Mild (1-3), orange-Moderate (4-6), grey-Severe (7-
10). * means p < 0.001. 
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Figure 3 Association between Pain Severity and Interference on Health Status Domains and 
general daily activities including facial status. Legend: sky blue-Mild (1-3), orange-Moderate 
(4-6), grey-Severe (7-10). * means p < 0.001. 
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Summary:  Evaluating the impact of trigeminal neuralgia. 
This cohort of 225 patients with trigeminal neuralgia describes the demographics and clinical 
features and  provides evidence for the significant psychosocial disability of the condition. 
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Table 1 Surgery type and effectiveness for 23 patients 
 
 
Note: some patients had multiple surgeries 
 
 
  Effectiveness (n) 
Surgery type Complete Partial No effect 
Gamma Knife 3 0 0 
Glycerol 4 5 2 
MVD 5 5 0 
Peripheral 1 0 1 
RFT 3 0 2 
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Table 2 Characteristics for 225 TN patients. 
Characteristic Value (n = 225) 
Age in years, mean (SD) 60.9 (12.5) 
Age at first attack, median [IQR] 57.0 [46.0, 65.0] 
Duration of TN in years, median [IQR] 4.0 [2.0, 7.0] 
Female 143 (63.6) 
Ethnicity  
   Asian 25 (11.0) 
   Caucasian 189 (83.5) 
   Others 12 (5.5) 
Index of multiple deprivation 
      1 (least deprived) 64 (28.4) 
     2 47 (20.9) 
     3 47 (20.9) 
     4 42 (18.7) 
     5(most deprived) 25 (11.1) 
Profession classification 
    Higher managerial, administrative and 
professional occupations 28 (12.6) 
   Intermediate occupations 52 (23.3) 
   Lower managerial, administrative and 
professional occupations 62 (27.8) 
   Lower supervisory and technical 
10 (4.5) 
7DEOH
occupations 
   Routine occupations 18 (8.1) 
   Semi-routine occupations 34 (15.2) 
   Small employers and own account 
workers 7 (3.1) 
   Unemployed 12 (5.4) 
Employment status 
    Employed full time 82 (36.6) 
   Employed part time 21 (9.4) 
   Full time homemaker 13 (5.8) 
   Retired 96 (42.9) 
   Unemployed 12 (5.4) 
Referrer to specialist clinic 
      Dentist 46 (20.6) 
     GP 102 (45.7) 
     Specialist 75 (33.6) 
Family history of TN 13 (5.8) 
Previous services used    
     GP 180 (80.0) 
     Dentist 161 (71.6) 
Dental Service 95 (42.2) 
     Dental Specialist 29 (12.9) 
     Oral Surgeon 74 (32.9) 
Dental Procedures 17 (7.6) 
Medical Service 132 (58.7) 
     ENT surgeon 13 (5.8) 
     Neurosurgeon 43 (19.1) 
     Neurologist 83 (36.9) 
     Physician 23 (10.2) 
     Psychiatrist 1 (0.4) 
     Psychologist 2 (0.9) 
     Pain Specialist 14 (6.2) 
Other medical procedures 34 (15.1) 
No. of secondary dental or medical 
services 
      0 40 (17.8) 
     1 112 (49.8) 
     2 53 (23.6) 
     3+ 20 (8.9) 
Note: values are presented as frequency (%) unless specified.  
 
Table 3 Associated factors and medical history stratified by the type of TN 
Associate factors and  
medical history 
Group 1  
TN 
n = 155 
Group 2 
TNC 
n = 32 
Group 3 
TNA 
n = 38 
P-trend 
Altered sensation or numbness 39 (25.3) 12 (40.0) 11 (28.9) 0.258 
Any autonomics unilateral 86 (55.5) 17 (53.1) 38 (100.0) <0.001 
   Swelling face 19 (12.3) 3 (10.0) 12 (31.6) 0.009 
   Redness of the face  14 (9.1) 2 (6.7) 13 (34.2) <0.001 
   Nasal stuffiness/runny 17 (11.0) 4 (13.3) 23 (60.5) <0.001 
   Eye redness 6 (3.9) 1 (3.3) 12 (31.6) <0.001 
   Eye tearing  18 (11.7) 7 (23.3) 22 (57.9) <0.001 
   Oedema eyelid 4 (2.6) 1 (3.3) 7 (18.4) <0.001 
   Earache 13 (8.4) 1 (3.3) 3 (7.9) 0.628 
   Fullness ears 8 (5.2) 3 (10.0) 6 (15.8) 0.080 
Headaches 37 (24.0) 6 (20.0) 10 (26.3) 0.829 
Migraines 17 (11.0) 3 (10.0) 7 (18.4) 0.426 
Migraines + TTH 12 (7.7) 1 (3.1) 3 (7.9) 0.638 
Bruxism 36 (23.7) 8 (26.7) 10 (26.3) 0.906 
Medical history 
 
   
Hypertension 57 (36.8) 14 (43.8) 13 (34.2) 0.690 
CVS 19 (12.3) 4 (12.5) 5 (13.2) 0.989 
Diabetes 10 (6.5) 2 (6.2) 0 (0.0) 0.276 
Deafness 17 (11.0) 1 (3.3) 2 (5.3) 0.272 
Ringing ears 18 (11.7) 0 (0.0) 2 (5.3) 0.083 
Other chronic pain 33 (21.3) 9 (28.1) 8 (21.1) 0.686 
   Neck pain 15 (9.9) 4 (13.3) 4 (10.5) 0.857 
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   Back pain 23 (15.1) 5 (17.2) 5 (13.2) 0.898 
Previous surgery TN 15 (9.7) 3 (9.4) 5 (13.2) 0.806 
Note: values are presented as frequency (%); P-trend represents comparison across three 
groups. 
 
Table 4 Pain characteristic stratified by the type of TN 
Pain characteristic 
Group 1 TN 
n = 155 
Group 2 TNC 
 n = 32 
Group 3 TNA 
 n = 38 
P-
trend 
V1 3 (1.9) 0 (0) 0 (0) 0.496 
V2 35 (22.7) 6 (18.8) 13 (33.3) 0.289 
V3 52 (33.8) 14 (43.8) 4 (10.3) 0.005 
V1 + V2 8 (5.2) 4 (12.5) 9 (23.1) 0.002 
V2 + V3 46 (29.9) 7 (21.9) 9 (23.1) 0.516 
V1 + V2 + V3 9 (5.8) 1 (3.1) 4 (10.3) 0.438 
Right 101 (65.6) 18 (56.2) 30 (76.9) 0.720 
Left 50 (32.5) 13 (40.6) 9 (23.1) 0.106 
Bilateral 3 (1.9) 1 (3.1) 0 (0.0) 0.587 
Intra oral 123 (79.9) 26 (81.2) 34 (87.2) 0.578 
Extra oral 83 (68.6) 17 (65.4) 22 (62.9) 0.802 
Predominant type of attack 
   
0.116 
   Single stab 71 (46.1) 11 (34.4) 18 (46.2)  
   Series of stabs 56 (36.4) 10 (31.3) 9 (23.1) 
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   Saw tooth 8 (5.2) 6 (18.8) 4 (10.3) 
 
   Single stab + Series of stabs 19 (12.3) 5 (15.6) 8 (20.5)  
Pain severity, median [IQR] 
    
   Worse 10.0 [8.0, 10.0] 9.0 [7.0, 10. 0] 10.0 [8.0, 10.0] 0.715 
   Average 5.0 [3.0, 7.0] 6.0 [4.0, 8.0] 5.0 [3.0, 7.0] 0.298 
   Least 0.0 [0.0, 3.0] 2.0 [0.0, 6.0] 2.0 [0.0, 5.0] 0.043 
Circumstances    0.001 
   Acute 48 (34.0) 10 (34.5) 11 (30.6)  
   Memorable 60 (42.6) 4 (13.8) 20 (55.6)  
   Slow to develop 27 (19.1) 9 (31.0) 4 (11.1)  
   Cannot remember 6 (4.3) 6 (20.7) 1 (2.8)  
Frequency of pain attack 
   
0.865 
   Hourly 11 (8.7) 1 (4.0) 2 (6.2) 
 
   Daily 115 (91.3) 24 (96.0) 30 (93.8) 
 
Duration of attacks  
   
0.872 
   Seconds 105 (69.5) 20 (66.7) 24 (61.5) 
 
   Minutes 42 (27.8) 9 (30.0) 13 (33.3) 
 
   1-4 hours 4 (2.6) 1 (3.3) 2 (5.1) 
 
Pain after main attack 50 (36.0) 20 (62.5) 17 (45.9) 0.020 
Length of remission 
   
0.385 
   None 12 (9.0) 2 (6.7) 6 (17.1) 
 
   Days 16 (11.9) 1 (3.3) 3 (8.6) 
 
   Weeks 70 (52.2) 14 (46.7) 16 (45.7) 
 
   Months 23 (17.2) 6 (20.0) 5 (14.3) 
 
   Years 13 (9.7) 7 (23.3) 5 (14.3) 
 
Remission period change 
   
0.470 
   No change 42 (31.6) 5 (19.2) 14 (37.8) 
 
   Shorter 84 (63.2) 18 (69.2) 21 (56.8) 
 
   Longer 7 (5.3) 3 (11.5) 2 (5.4) 
 
Provoking factors      
Spontaneous pain 151 (98.1) 32 (100.0) 38 (97.4) 0.690 
Provoked by light touch 143 (92.9) 29 (90.6) 39 (100.0) 0.187 
Provoked by other factors 
    
   Cold wind/weather 80 (51.9) 10 (31.2) 23 (59.0) 0.050 
   Bodily movement 65 (42.2) 12 (37.5) 24 (61.5) 0.063 
   Noise or light 3 (1.9) 0 (0.0) 1 (2.6) 0.690 
   Alcohol 1 (0.6) 0 (0.0) 0 (0.0) 0.793 
McGill pain questionnaire     
 
   Number of words chosen (mean ± sd) 10.3 ± 3.8 12.2 ± 3.9 12.3 ± 2.8 0.003 
   Pain rating index (mean ± sd) 27.7 ± 12.1 32.8 ± 14.4 31.9 ± 8.4 0.044 
   Sensory groups Shooting (110) Shooting (24) Shooting (29) 
 
 
Sharp (93) Sharp (21) Sharp (26) 
 
 
Stabbing (73) Stabbing (14) Stabbing (20) 
 
   Affective Vicious (43) Terrifying (8) Wretched (13)   
 Terrifying (39) Fearful (6) Fearful (12)  
   Evaluative Unbearable (58) Unbearable (16) Unbearable (13)  
   Miscellaneous Piercing (57) Piercing (14) Piercing (16)  
HAD-Anxiety     
   Nil 72 (53.3) 16 (59.3) 8 (22.2)  
   Mild 29 (21.5) 3 (11.1) 18 (50.0) 0.001 
   Severe 34 (25.2) 8 (29.6) 10 (27.8)  
HAD-Depression     
   Nil 95 (69.3) 19 (70.4) 16 (44.4)  
   Mild 21 (15.3) 5 (18.5) 8 (22.2) 0.047 
   Severe 21 (15.3) 3 (11.1) 12 (33.3)  
Brief pain inventory, median [IQR]     
   Pain severity index 3.50 [2.00, 5.25] 3.50 [2.25, 6.25] 5.00 [3.25, 6.31] 0.090 
   Pain interference-general daily life 2.71 [1.14, 5.29] 3.14 [0.57, 4.57] 3.29 [1.71, 6.00] 0.380 
   Pain interference-facial status 4.57 [2.07, 7.14] 7.00 [2.43, 7.86] 5.93 [2.21, 7.71] 0.349 
Note: values are presented as frequency (%) unless specified; P-trend represents comparison across three group 
 
Table 5  Association between HAD-anxiety and depression and graded chronic pain 
scale in patients with trigeminal neuralgia and its variants. 
  Graded chronic pain scale 
HAD-Anxiety    Grade 1    Grade 2    Grade 3    Grade 4 
   Nil 19 30 13 19 
   Mild 2 17 5 17 
   Severe 1 5 7 25 
HAD- Depression      
   Nil 18 41 19 26 
   Mild 3 5 3 16 
   Severe 1 6 5 19 
Pearson's Chi-square test: p-value < 0.001 
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Table 6 Association between HAD-anxiety and depression and Brief Pain Inventory 
(BPI) pain severity in patients with trigeminal neuralgia and its variants. 
 
  BPI pain severity 
HAD-Anxiety*  
No pain/ 
not reported 
Mild Moderate Severe 
   Nil 12 29  33 11 
   Mild 3 12  21 10 
   Severe 1 14  20 12 
HAD- Depression**     
   Nil 12 42  41 17 
   Mild 3 6  22 5 
   Severe 2 8  11 11 
 *Pearson's Chi-square test: p-value = 0.163 **Pearson's Chi-square test: p-value = 0.022 
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